新たに診断された高リスク神経芽細胞腫の子供の通常の支持ケアへの公平(上昇)をサポートするための資源介入の追加のランダム化第II相試験評価評価 (RISE in HR NBL)
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Participants will be randomized to receive one of the following for 6-months:
- Usual supportive care alone or
- Usual supportive care plus Pediatric RISE
調査の概要
詳細な説明
This is a randomized Phase II trial evaluating the addition of the RISE supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. Participants will be randomized into one of two groups: Usual supportive care or Pediatric RISE plus usual supportive care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, in-person or virtual appointments, and surveys.
Participation in this research study is expected to last for about 6-months.
It is expected that about 84 participants will take part in this research study.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Kira Bona, MD, MPH
- 電話番号:617-632-4688
- メール:Kira_Bona@dfci.harvard.edu
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Children's Hospital Colorado
-
コンタクト:
- Katherine Lind, MD
- メール:Katherine.Lind@childrenscolorado.org
-
コンタクト:
- Navin Pinto, MD
- メール:Navin.Pinto@childrenscolorado.org
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- 募集
- Connecticut Children's Medical Center
-
コンタクト:
- Andrea Orsey, MD, MSCE
- 電話番号:860-545-9630
- メール:aorsey@connecticutchildrens.org
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- 募集
- Children's Healthcare of Atlanta
-
コンタクト:
- Thomas Cash, MD
- 電話番号:404-785-1200
- メール:william.cash@choa.org
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、03079
- 募集
- Dana-Farber Cancer Institute
-
コンタクト:
- Kira Bona, MD, MPH
- 電話番号:203-464-9417
- メール:kira.bona@childrens.harvard.edu
-
-
New York
-
New York、New York、アメリカ、10027
- 募集
- Columbia University Medical Center
-
コンタクト:
- Melissa Beauchemin, MD
-
コンタクト:
- Justine Kahn, MD
- メール:jk2034@cumc.columbia.edu
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- 募集
- Cincinnati Children's Hospital Medical Center
-
コンタクト:
- Katherine Somers, MD
- メール:katherine.somers@cchmc.org
-
コンタクト:
- Meera Kotagal, MD
- メール:meera.kotagal@cchmc.org
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
コンタクト:
- Rochelle Bagatell, MD
- 電話番号:267-426-9737
- メール:bagatellr@chop.edu
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas Southwestern Medical Center
-
コンタクト:
- Puja Umaretiya, MD
- 電話番号:(214) 456-2382
- メール:puja.umaretiya@utsouthwestern.edu
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- 募集
- Seattle Children's Hospital
-
コンタクト:
- Anurekha Hall, MD
- 電話番号:206-987-2106
- メール:anurekha.hall@seattlechildrens.org
-
コンタクト:
- Kristine Karvonen, MD
- メール:Kristine.Karvonen@seattlechildrens.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.
- Patient newly diagnosed with high-risk neuroblastoma
- Patient has established care at study site and initiated cancer-directed therapy
- Patient has not yet initiated Induction Cycle 3
- Patient aged 0-17 years at the time of consent
- Parent/guardian screened positive for self-reported low-income (<200% Federal Poverty) *
- Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
- Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
- Patients of all languages are eligible to participate
Exclusion Criteria:
- Foreign national family receiving care as an Embassy-pay patient.
- Child or household member receiving SSI
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm 1: RISE Intervention + Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete:
|
Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
他の名前:
|
|
介入なし:Arm 2: Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Household Material Hardship (HMH) Score Reduction Rate
時間枠:Baseline (T1) and 6-months (end-intervention; T3)
|
HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis. |
Baseline (T1) and 6-months (end-intervention; T3)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pediatric-Modified Comprehensive Score for Financial Toxicity (COST)
時間枠:3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
Financial toxicity will be assessed with the 12-item modified COST measure. Each item is rated on a 0-4 scale, yielding a total score range of 0-48, with higher scores indicating better financial well-being. The final COST score will be calculated per established methods. A change of approximately 5 points is considered a minimally important difference (MID), representing a clinically meaningful change in financial toxicity. |
3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
|
Parent Psychological Distress (Kessler-6) Score Change from Baseline to 6 Months
時間枠:Baseline (T1) and 6-months (end-intervention; T3)
|
Psychological distress will be assessed using the 6-item Kessler-6 scale. The scale includes 6 items scored from 0 ('none of the time') to 4 ('all of the time'), yielding a total score ranging from 0 to 24, with higher scores indicating greater psychological distress. A reduction in scores of approximately 2.8 points is considered a minimally important difference (MID), representing a clinically meaningful improvement in psychological distress. |
Baseline (T1) and 6-months (end-intervention; T3)
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities Score Change from Baseline to 6 Months
時間枠:Baseline (T1) and 6-months (end-intervention; T3)
|
The PROMIS Applied Cognition-Abilities short form is an 8-item measure assessing subjective learning and memory, attention and concentration, executive function, and processing speed. Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived cognitive function. |
Baseline (T1) and 6-months (end-intervention; T3)
|
協力者と研究者
捜査官
- 主任研究者:Kira Bona, MD, MPH、Dana-Farber Cancer Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 24-600
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Dr. Kira Bona. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 共有時間枠
Data can be shared no earlier than 1 year following the date of publication
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。